Poolbeg Pharma’s (POLB) “House Stock” Rating Reaffirmed at Shore Capital Group

Poolbeg Pharma (LON:POLB – Get Free Report)‘s stock had its “house stock” rating reiterated by Shore Capital Group in a note issued to investors on Thursday, London Stock Exchange reports.

Poolbeg Pharma Trading Down 4.0%

Shares of LON POLB opened at GBX 8.69 on Thursday. The stock has a market cap of £66.34 million, a P/E ratio of -9.24 and a beta of 1.83. The stock has a 50 day moving average of GBX 7.94 and a two-hundred day moving average of GBX 6.35. Poolbeg Pharma has a twelve month low of GBX 3.30 and a twelve month high of GBX 9.30.

Get Poolbeg Pharma alerts:

About Poolbeg Pharma

(Get Free Report)

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.

Featured Stories

• Five stocks we like better than Poolbeg Pharma
• Chips to Bots: Qualcomm’s Agentic AI Breakout
• Ciena Fell 40%—Now One Analyst Sees 50% Upside
• Energy Transfer Taps the AI Power Boom
• Viking’s Obesity Edge May Be Staying Power, Not Weight Loss

Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.